Ekso Bionics Holdings, Inc.

Greetings. Welcome to the ExoBionics first quarter 2022 financial results call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the call over to your host, Andrew Blazier of Finn Partners. Thank you. You may begin.

Thank you, Devin, and thank you all for participating in today's call. Joining me from Exobionics are Stephen Sherman, Chairman and Chief Executive Officer, Scott Davis, President and Chief Operating Officer, and Jack Glenn, Chief Financial Officer. Earlier today, Exobionics released financial results for the first quarter ended March 31, 2022. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operational expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. EXO disclaims any intention or obligation except as required by law to update or revise any financial or operational projections our regulatory outlook, or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the broadcast today, April 28, 2022. I will now turn the call over to Exobionics Chairman and CEO, Stephen Sherman.

Thank you, Andrew, and thank you, everyone, for joining us today. We're off to a strong start in 2022. Revenues in the first quarter are up by more than 30% year over year, and we are seeing momentum in both our ExoHealth and our ExoWorks business segments. Our customers recognize the value and benefits that wearable exoskeletons bring to both patients and essential workers. Our balance sheet remains strong. We are focused. We have a cohesive team of professionals and our products continue to be leading edge and innovative. We are executing our strategy of deepening relationship with network operators, expanding our presence in industrial markets, and strengthening the foundation of the business to drive shareholders' value. Now, I will turn the call over to our President and Chief Operating Officer, Scott Davis.